10:20:55 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Prenumeration

Kalender

2024-10-24 Kvartalsrapport 2024-Q3
2024-07-11 Kvartalsrapport 2024-Q2
2024-05-08 Ordinarie utdelning ATORX 0.00 SEK
2024-05-07 Årsstämma 2024
2024-05-06 Kvartalsrapport 2024-Q1
2024-03-14 Extra Bolagsstämma 2024
2024-02-09 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-07-13 Kvartalsrapport 2023-Q2
2023-05-26 Årsstämma 2023
2023-05-04 Ordinarie utdelning ATORX 0.00 SEK
2023-04-25 Kvartalsrapport 2023-Q1
2023-04-14 Extra Bolagsstämma 2022
2023-02-10 Bokslutskommuniké 2022
2022-10-20 Kvartalsrapport 2022-Q3
2022-07-12 Kvartalsrapport 2022-Q2
2022-05-06 Ordinarie utdelning ATORX 0.00 SEK
2022-05-05 Årsstämma 2022
2022-04-27 Kvartalsrapport 2022-Q1
2022-02-11 Bokslutskommuniké 2021
2021-11-08 Extra Bolagsstämma 2021
2021-10-21 Kvartalsrapport 2021-Q3
2021-07-13 Kvartalsrapport 2021-Q2
2021-06-01 Årsstämma 2021
2021-05-03 Ordinarie utdelning ATORX 0.00 SEK
2021-04-27 Kvartalsrapport 2021-Q1
2021-02-26 Bokslutskommuniké 2020
2020-10-22 Kvartalsrapport 2020-Q3
2020-07-13 Kvartalsrapport 2020-Q2
2020-05-06 Ordinarie utdelning ATORX 0.00 SEK
2020-05-05 Årsstämma 2020
2020-04-23 Kvartalsrapport 2020-Q1
2020-02-12 Bokslutskommuniké 2019
2019-10-24 Kvartalsrapport 2019-Q3
2019-07-11 Kvartalsrapport 2019-Q2
2019-05-10 Ordinarie utdelning ATORX 0.00 SEK
2019-05-09 Årsstämma 2019
2019-04-17 Kvartalsrapport 2019-Q1
2019-02-14 Bokslutskommuniké 2018
2018-10-26 Kvartalsrapport 2018-Q3
2018-07-12 Kvartalsrapport 2018-Q2
2018-04-27 Ordinarie utdelning ATORX 0.00 SEK
2018-04-26 Kvartalsrapport 2018-Q1
2018-04-26 Årsstämma 2018
2018-02-16 Bokslutskommuniké 2017
2017-10-25 Kvartalsrapport 2017-Q3
2017-08-23 Kvartalsrapport 2017-Q2
2017-05-03 Ordinarie utdelning ATORX 0.00 SEK
2017-05-02 Årsstämma 2017
2017-05-02 Kvartalsrapport 2017-Q1
2017-02-17 Bokslutskommuniké 2016
2016-11-14 Kvartalsrapport 2016-Q3

Beskrivning

LandSverige
ListaSmall Cap Stockholm
SektorHälsovård
IndustriBioteknik
Alligator Bioscience är ett forskningsbaserat bioteknikbolag som använder en patenterad teknologi för att utveckla biologiska läkemedelskandidater inom inflammation och cancer. Bolaget är verksamt i den tidigare delen av läkemedelsutvecklingskedjan. Bolaget har en global teknologiplattform och är aktivt inom ett snabbt växande segment på läkemedelsmarknaden – proteinläkemedel.
2024-03-26 08:30:00

Lund, Sweden – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces the publication of a scientific article featuring its novel bispecific antibody format RUBY® in the peer-reviewed journal mAbs.

  • RUBY® is a novel bispecific antibody format with excellent functionality including IgG-like stability, pharmacology and developability properties
  • The RUBY® format allows rapid generation of bispecific antibodies (bsAbs) that fulfill key drug development criteria and mitigates many of the challenges associated to other bsAb formats

The article, entitled "RUBY® - A tetravalent (2+2) bispecific antibody format with excellent functionality and IgG-like stability, pharmacology and developability properties", highlights how:

  • RUBY® allows rapid generation of bsAbs with high developability
  • RUBY® bsAbs are compatible with small-scale production systems for screening purposes, can be produced at high yields from production cell lines, contain low amounts of aggregates, display favorable solubility and stress endurance profiles, are compatible with various IgG isotypes, and and allows for tailored Fc gamma receptor interactions
  • Retained interaction with Fc neonatal receptors is demonstrated to translate into a mAb-like pharmacokinetic profile
  • Functionality of conditionally active RUBY® bsAbs is confirmed in vitro, and RUBY® bsAbs are shown to penetrate and localize to tumor tissue in vivo

"The publication of this article in the renowned scientific journal mAbs is an important recognition of our bispecific antibody format RUBY®. It demonstrates its great developability and its place as a key part of our proprietary drug discovery engine for the development of innovative drugs for hard-to-treat cancers," said Laura von Schantz, CTO at Alligator Bioscience. "The article in particular demonstrates how our RUBY® format has attractive mAb-like attributes and offers the possibility to mitigate many of the development and bioprocessing challenges linked to other bsAb formats, facilitating both high functionality and developability and making it a valuable contributor to the next generation of bsAbs."

Alligator’s RUBY® format is an important proprietary technology used both in internal and partnered programs.

The full article is available online via this link.